{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:50:46Z","timestamp":1788958246813,"version":"build-2803163510"},"reference-count":288,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immunotherapy has revolutionized cancer treatment, offering novel therapeutic strategies such as immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines. However, these modalities are associated with varying cardiovascular toxicities that may affect treatment continuation and patient outcomes. Cardiovascular complications from ICIs, such as myocarditis (incidence 0.04\u20131.14%, mortality 25\u201350%), arrhythmias, heart failure, and thromboembolic events, are primarily mediated by autoreactive T-cell activation and immune-related inflammation. CTLA-4 and PD-1\/PD-L1 blockade disrupts immune homeostasis, leading to direct myocardial infiltration and cytokine-mediated damage. Up to 26% of patients receiving CAR T-cell therapy develop cardiovascular events, often secondary to cytokine release syndrome (CRS). Excessive release of pro-inflammatory cytokines (e.g., IL-6, IFN-\u03b3) leads to endothelial dysfunction, hypotension, myocardial depression, arrhythmias, and acute coronary syndromes. Rare cases of myocarditis and arrhythmias have been reported following mRNA vaccine administration, particularly in younger males. Proposed mechanisms include innate immune activation via Toll-like receptors, leading to cytokine release and myocardial inflammation. Dendritic cell vaccines show lower cardiovascular toxicity, likely due to their localized and cell-specific immune activation. This review provides a comprehensive evaluation of cardiovascular adverse events across immunotherapy classes. It underscores the importance of early detection through biomarkers, risk stratification, and multidisciplinary cardio-oncology collaboration. Future research should aim to refine immunotherapy protocols to minimize cardiotoxic risks while preserving anti-tumor efficacy.<\/jats:p>","DOI":"10.3389\/fonc.2025.1601808","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:15:04Z","timestamp":1750205704000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Cardiovascular adverse effects of immunotherapy in cancer: insights and implications"],"prefix":"10.3389","volume":"15","author":[{"given":"Haiping","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.cr.7310118","article-title":"Beyond tumorigenesis: cancer stem cells in metastasis","volume":"17","author":"Li","year":"2007","journal-title":"Cell Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-09968-2","article-title":"Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment","volume":"26","author":"Saleh","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/86297","article-title":"A fresh look at tumor immunosurveillance and immunotherapy","volume":"2","author":"Smyth","year":"2001","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1714680","article-title":"A milestone for CAR T cells","volume":"377","author":"Tran","year":"2017","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31205","article-title":"DC-based cancer vaccines","volume":"117","author":"Gilboa","year":"2007","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000043","article-title":"Toxicity management for patients receiving novel T-cell engaging therapies","volume":"26","author":"Barrett","year":"2014","journal-title":"Curr Opin Pediatr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.038","article-title":"Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio-immuno-oncology","volume":"71","author":"Tocchetti","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B13","first-page":"85","article-title":"Global burden of cancer","volume":"79","author":"Ma","year":"2006","journal-title":"Yale J Biol Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3033279","article-title":"Assessment of the evolution of cancer treatment therapies","volume":"3","author":"Arruebo","year":"2011","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S1470-2045(19)30658-8","article-title":"Earlier diagnosis: the importance of cancer symptoms","volume":"21","author":"Whitaker","year":"2020","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejphar.2009.09.067","article-title":"Immunotherapy of cancer","volume":"625","author":"Borghaei","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1188\/22.CJON.54-60","article-title":"Immune checkpoint inhibitor-related myocarditis: recognition, surveillance, and management","volume":"26","author":"Kuhnly","year":"2022","journal-title":"Clin J Oncol Nurs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional FDA adverse events reporting system analysis","volume":"26","author":"Guha","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.07.017","article-title":"Cardiovascular considerations before cancer therapy: gaps in evidence and JACC: cardioOncology expert panel recommendations","volume":"6","author":"Raisi-Estabragh","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v6i32","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell Malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic Malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.045","article-title":"Immunotherapy: The path to win the war on cancer","volume":"161","author":"Topalian","year":"2015","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v6i42","article-title":"Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy","volume":"6","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"key":"B29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11912-021-01068-0","article-title":"Cardiovascular toxicities of CAR T-cell therapy","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0119-y","article-title":"CAR T cell therapy: inroads to response and resistance","volume":"19","author":"Brown","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor-modified T cells: CD19 and the road beyond","volume":"131","author":"Salter","year":"2018","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/cas.2017.108.issue-6","article-title":"Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"108","author":"Makita","year":"2017","journal-title":"Cancer Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/hon.v41.S1","article-title":"CAR T-cell therapy in large B cell lymphoma","volume":"41","author":"Boardman","year":"2023","journal-title":"Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153912","article-title":"Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: A systematic review and meta-analysis","volume":"13","author":"Lei","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.01.015","article-title":"The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma","volume":"22","author":"Cao","year":"2020","journal-title":"Cytotherapy"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010047","article-title":"Chimeric antigen receptor T-cell (CAR T) therapy for hematologic and solid Malignancies: efficacy and safety-A systematic review with meta-analysis","volume":"11","author":"Yu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11886-021-01440-3","article-title":"Immunotherapy-associated cardiotoxicity of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy: diagnostic and management challenges and strategies","volume":"23","author":"Stein-Merlob","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158242","article-title":"Cardiotoxicity of chimeric antigen receptor T-cell (CAR-T) therapy: pathophysiology, clinical implications, and echocardiographic assessment","volume":"23","author":"Nenna","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","volume":"107","author":"Stein-Merlob","year":"2021","journal-title":"Heart"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2018.20.issue-12","article-title":"Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological Malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.691064","article-title":"An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: A single-centre retrospective study","volume":"11","author":"Qi","year":"2021","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T cell therapy in children: A single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transpl"},{"key":"B51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: A retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transpl"},{"key":"B56","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolyt"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transpl"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01616","article-title":"How I manage: pathophysiology and management of toxicity of chimeric antigen receptor T-cell therapies","volume":"39","author":"Reagan","year":"2021","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"B67","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2976","article-title":"Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy","volume":"40","author":"Catal\u00e1","year":"2022","journal-title":"Hematol Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1371286","article-title":"Weight status change during four years and left ventricular hypertrophy in Chinese children","volume":"12","author":"Liu","year":"2024","journal-title":"Front Pediatr"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113445","article-title":"Complications after CD19+ CAR T-cell therapy","volume":"12","author":"Penack","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"117405","DOI":"10.1016\/j.jns.2021.117405","article-title":"Neurological complications of cancer immunotherapy (CAR T cells)","volume":"424","author":"Rubin","year":"2021","journal-title":"J Neurol Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-024-00252-y","article-title":"Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis","volume":"10","author":"Maleki","year":"2024","journal-title":"Cardio-Oncology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.924208","article-title":"Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.37222","article-title":"Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic Malignant neoplasms: A meta-analysis","volume":"7","author":"Koeckerling","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-Therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002303","article-title":"Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma","volume":"9","author":"Brammer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v205.3","article-title":"Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile","volume":"205","author":"Shouval","year":"2024","journal-title":"Br J Haematol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40959-023-00170-5","article-title":"Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study","volume":"9","author":"Lee","year":"2023","journal-title":"Cardio-oncol (London England)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"102504","DOI":"10.1016\/j.eclinm.2024.102504","article-title":"Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study","volume":"69","author":"Korell","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh194","article-title":"PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells","volume":"17","author":"Iwai","year":"2005","journal-title":"Int Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: cardioOncology primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812186116","article-title":"Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody","volume":"116","author":"Ha","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.04.010","article-title":"Mechanisms of foxp3+ T regulatory cell-mediated suppression","volume":"30","author":"Shevach","year":"2009","journal-title":"Immunity"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B103","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(05)80055-8","article-title":"Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7\/BB1 in interleukin-2 production and immunotherapy","volume":"71","author":"Schwartz","year":"1992","journal-title":"Cell"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.14.1.233","article-title":"CD28\/B7 system of T cell costimulation","volume":"14","author":"Lenschow","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol Rev"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1126\/science.7694361","article-title":"Identification of an alternative CTLA-4 ligand costimulatory for T cell activation","volume":"262","author":"Hathcock","year":"1993","journal-title":"Science"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1126\/science.7694363","article-title":"Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation","volume":"262","author":"Freeman","year":"1993","journal-title":"Science"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/366076a0","article-title":"B70 antigen is a second ligand for CTLA-4 and CD28","volume":"366","author":"Azuma","year":"1993","journal-title":"Nature"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.13.5031","article-title":"T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7\/BB-1","volume":"87","author":"Linsley","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J Exp Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162359999","article-title":"Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors","volume":"99","author":"Riley","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1126\/science.1131078","article-title":"Reversal of the TCR stop signal by CTLA-4","volume":"313","author":"Schneider","year":"2006","journal-title":"Science"},{"key":"B116","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1074-7613(01)00259-X","article-title":"Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength","volume":"16","author":"Egen","year":"2002","journal-title":"Immunity"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3475","article-title":"Cutting edge: CTLA-4 (CD152) differentially regulates mitogen-activated protein kinases (extracellular signal-regulated kinase and c-Jun N-terminal kinase) in CD4+ T cells from receptor\/ligand-deficient mice","volume":"169","author":"Schneider","year":"2002","journal-title":"J Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1159\/000490025","article-title":"Evolving roles for targeting CTLA-4 in cancer immunotherapy","volume":"47","author":"Zhao","year":"2018","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/82_2010_114","article-title":"LAG-3 in cancer immunotherapy","volume":"344","author":"Goldberg","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31184","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems","volume":"117","author":"Grosso","year":"2007","journal-title":"J Clin Invest"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.v9i5-6","article-title":"The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"B129","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","article-title":"Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy","volume":"35","author":"Ascierto","year":"2017","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx440.011","article-title":"LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti\u2013PD-1\/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched","volume":"28","author":"Ascierto","year":"2017","journal-title":"Ann Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.v11.3","article-title":"LAG3 and its emerging role in cancer immunotherapy","volume":"11","author":"Wang","year":"2021","journal-title":"Clin Trans Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.12701\/yujm.2021.01312","article-title":"An update on immunotherapy with PD-1 and PD-L1 blockade","volume":"38","author":"Koh","year":"2021","journal-title":"Yeungnam Univ J Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3016","article-title":"IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells","volume":"75","author":"Sun","year":"2015","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B142","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.9.5923","article-title":"NF-kappaB induces expression of the Bcl-2 homologue A1\/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis","volume":"19","author":"Wang","year":"1999","journal-title":"Mol Cell Biol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.116","article-title":"Cardiovascular toxicity with CTLA-4 inhibitors in cancer patients: A meta-analysis","volume":"3","author":"Liu","year":"2024","journal-title":"Cancer Innov"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.969942","article-title":"Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022","volume":"9","author":"Wu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3390\/biology12030472","article-title":"Immune checkpoint inhibitor associated myocarditis and cardiomyopathy: A translational review","volume":"12","author":"Wang","year":"2023","journal-title":"Biol (Basel)"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D\u2019Souza","year":"2021","journal-title":"Eur Heart J"},{"key":"B155","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40959-021-00097-9","article-title":"Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center","volume":"7","author":"Waheed","year":"2021","journal-title":"Cardio-oncol (London England)"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B157","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","article-title":"Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome","volume":"3","author":"Geisler","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B158","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.2014.28.issue-3","article-title":"Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database","volume":"28","author":"Honton","year":"2014","journal-title":"Fundam Clin Pharmacol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"B162","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet (London England)"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0121","article-title":"Acute myocarditis: aetiology, diagnosis and management","volume":"21","author":"Lampejo","year":"2021","journal-title":"Clin Med"},{"key":"B164","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.hrthm.2018.11.024","article-title":"Arrhythmias in myocarditis: State of the art","volume":"16","author":"Peretto","year":"2019","journal-title":"Hear Rhythm"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2007.03.012","article-title":"Roles of programmed death-1 (PD-1)\/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3","volume":"75","author":"Seko","year":"2007","journal-title":"Cardiovasc Res"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01047-10","article-title":"Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1","volume":"79","author":"Gutierrez","year":"2011","journal-title":"Infect Immun"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"B170","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1313140","article-title":"Cancer-drug discovery and cardiovascular surveillance","volume":"369","author":"Groarke","year":"2013","journal-title":"N Engl J Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051145","article-title":"Immune checkpoint inhibitors-associated cardiotoxicity","volume":"14","author":"Li","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"B176","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1172\/JCI44583","article-title":"Impaired thymic tolerance to \u03b1-myosin directs autoimmunity to the heart in mice and humans","volume":"121","author":"Lv","year":"2011","journal-title":"J Clin Invest"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"B179","doi-asserted-by":"publisher","first-page":"103016","DOI":"10.1016\/j.redox.2023.103016","article-title":"M2 macrophage exosome-derived lncRNA AK083884 protects mice from CVB3-induced viral myocarditis through regulating PKM2\/HIF-1\u03b1 axis mediated metabolic reprogramming of macrophages","volume":"69","author":"Zhang","year":"2024","journal-title":"Redox Biol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"158093","DOI":"10.1016\/j.cej.2024.158093","article-title":"Nanozyme-enhanced tyramine signal amplification probe for preamplification-free myocarditis-related miRNAs detection","volume":"503","author":"Li","year":"2025","journal-title":"Chem Eng J"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c05847","article-title":"Multitargeted immunomodulatory therapy for viral myocarditis by engineered extracellular vesicles","volume":"18","author":"Pei","year":"2024","journal-title":"ACS Nano"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-024-01472-w","article-title":"Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia","volume":"42","author":"Peng","year":"2024","journal-title":"Invest New Drugs"},{"key":"B183","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.celrep.2019.06.007","article-title":"The cardiac microenvironment instructs divergent monocyte fates and functions in myocarditis","volume":"28","author":"Hou","year":"2019","journal-title":"Cell Rep"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132126","article-title":"Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy","volume":"211","author":"Wu","year":"2014","journal-title":"J Exp Med"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85851","article-title":"Cardiac myosin-Th17 responses promote heart failure in human myocarditis","volume":"1","author":"Myers","year":"2016","journal-title":"JCI Insight"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903369","article-title":"Cutting edge: CTLA-4\u2013B7 interaction suppresses Th17 cell differentiation","volume":"185","author":"Ying","year":"2010","journal-title":"J Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.213157","article-title":"Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy","volume":"106","author":"Baldeviano","year":"2010","journal-title":"Circ Res"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"B190","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00395-024-01068-8","article-title":"Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors","volume":"120","author":"Gergely","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S324349","article-title":"Cardiovascular adverse events reported from COVID-19 vaccines: A study based on WHO database","volume":"14","author":"Jeet Kaur","year":"2021","journal-title":"Int J Gen Med"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.5511","article-title":"Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older","volume":"181","author":"Simone","year":"2021","journal-title":"JAMA Intern Med"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after covid-19 vaccination in a large health care organization","volume":"385","author":"Witberg","year":"2021","journal-title":"N Engl J Med"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B195","doi-asserted-by":"publisher","first-page":"102524","DOI":"10.1016\/j.autrev.2020.102524","article-title":"Could Sars-coronavirus-2 trigger autoimmune and\/or autoinflammatory mechanisms in genetically predisposed subjects","volume":"19","author":"Caso","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313499959","article-title":"Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines","volume":"23","author":"Rinaldi","year":"2014","journal-title":"Lupus"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8597-x","article-title":"Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases","volume":"60","author":"Perricone","year":"2014","journal-title":"Immunol Res"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279075","article-title":"Post-mortem findings in vaccine-induced thrombotic thombocytopenia","volume":"106","author":"Pomara","year":"2021","journal-title":"Haematologica"},{"key":"B199","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1002\/iid3.v11.3","article-title":"Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia","volume":"11","author":"Yasmin","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab901","article-title":"Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: low incidence and mild severity","volume":"43","author":"Liuzzo","year":"2022","journal-title":"Eur Heart J"},{"key":"B201","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.50.1.507","article-title":"Dendritic cell vaccines for cancer immunotherapy","volume":"50","author":"Timmerman","year":"1999","journal-title":"Annu Rev Med"},{"key":"B203","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12032-023-02060-3","article-title":"The future of cancer immunotherapy: DNA vaccines leading the way","volume":"40","author":"Pandya","year":"2023","journal-title":"Med Oncol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205163","article-title":"Neoantigen vaccines; clinical trials, classes, indications, adjuvants and combinatorial treatments","volume":"14","author":"Niemi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B207","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-230X-11-30","article-title":"Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - case report","volume":"11","author":"Popescu","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"e14489","DOI":"10.1111\/cns.14489","article-title":"A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response","volume":"30","author":"Duan","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"B209","doi-asserted-by":"publisher","first-page":"112178","DOI":"10.1016\/j.intimp.2024.112178","article-title":"Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy","volume":"134","author":"Fang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200212000-00008","article-title":"A case of reversible dilated cardiomyopathy after alpha-interferon therapy in a patient with renal cell carcinoma","volume":"324","author":"Kuwata","year":"2002","journal-title":"Am J Med Sci"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01836.x","article-title":"Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects","volume":"56","author":"Gupta","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"B212","article-title":"Pericarditis due to interferon-alpha therapy during treatment for chronic hepatitis C","volume":"67","author":"Gressens","year":"2004","journal-title":"Acta Gastroenterol Belg"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9935-7","article-title":"Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma","volume":"29","author":"Rauw","year":"2012","journal-title":"Med Oncol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2013.08.002","article-title":"Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C","volume":"8","author":"Sakabe","year":"2013","journal-title":"J Cardiol cases"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2009.09.084","article-title":"Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient","volume":"89","author":"Wang","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05999.x","article-title":"Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C","volume":"97","author":"Kumar","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1086\/cid.2004.39.issue-11","article-title":"Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature","volume":"39","author":"Midturi","year":"2004","journal-title":"Clin Infect"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-009-0075-y","article-title":"Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C","volume":"2","author":"Kaneko","year":"2009","journal-title":"Clin J Gastroenterol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-008-0817-8","article-title":"Extremely acute exacerbation of interstitial pneumonia after interferon-alpha treatment for metastatic renal cell carcinoma","volume":"14","author":"Ando","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"B220","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4166\/kjg.2011.58.1.47","article-title":"Interstitial pneumonitis in a patient with chronic hepatitis C and chronic renal failure on interferon therapy","volume":"58","author":"Kang","year":"2011","journal-title":"Kor J Gastroenterol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.2013.20.issue-4","article-title":"Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin","volume":"20","author":"Foster","year":"2013","journal-title":"J Viral Hepat"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.10.761","article-title":"Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis","volume":"55","author":"Vlachoyiannopoulos","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00701.x","article-title":"Coronary vasospasm after interferon administration","volume":"81","author":"Yamamoto","year":"1998","journal-title":"Br J Urol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11886-024-02184-6","article-title":"Eosinophilic myocarditis: A concise review","volume":"27","author":"Asada","year":"2025","journal-title":"Curr Cardiol Rep"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1159\/000336839","article-title":"Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab","volume":"159","author":"Vultaggio","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun (London England)"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000626","article-title":"Toxicities from antibody-drug conjugates","volume":"28","author":"Johns","year":"2022","journal-title":"Cancer J"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B229","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210308","article-title":"Target and cell therapy for atherosclerosis and CVD","volume":"24","author":"Markina","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B233","doi-asserted-by":"publisher","first-page":"101613","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2204228","article-title":"High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated Malignancies: a pharmacovigilance study based on the FAERS database","volume":"22","author":"Ma","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: A pragmatic approach to the american and european cardio-oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B236","doi-asserted-by":"publisher","first-page":"15","DOI":"10.34133\/cbsystems.0015","article-title":"Ultrafast miniature robotic swimmers with upstream motility","volume":"4","author":"Wang","year":"2023","journal-title":"Cyborg Bionic Syst (Washington DC)"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2277801","article-title":"A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system","volume":"23","author":"Sun","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B238","doi-asserted-by":"publisher","first-page":"e402","DOI":"10.1002\/ctm2.v11.5","article-title":"Loss of m6A demethylase ALKBH5 promotes post-ischemic angiogenesis via post-transcriptional stabilization of WNT5A","volume":"11","author":"Zhao","year":"2021","journal-title":"Clin Transl Med"},{"key":"B239","doi-asserted-by":"publisher","first-page":"155354","DOI":"10.1016\/j.prp.2024.155354","article-title":"Cause and consequence of heterogeneity in human mesenchymal stem cells: Challenges in clinical application","volume":"260","author":"Lyu","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01077-7","article-title":"Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients","volume":"120","author":"Panuccio","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1124\/mol.117.110650","article-title":"Long noncoding RNA LINC00657 acting as a miR-590-3p sponge to facilitate low concentration oxidized low-density lipoprotein-induced angiogenesis","volume":"93","author":"Bao","year":"2018","journal-title":"Mol Pharmacol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1109\/JBHI.2025.3540712","article-title":"Fast virtual stenting for thoracic endovascular aortic repair of aortic dissection using graph deep learning","author":"Zhang","year":"2025","journal-title":"IEEE J BioMed Heal Inf"},{"key":"B243","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-025-02591-1","article-title":"The triglyceride-glucose index and its obesity-related derivatives as predictors of all-cause and cardiovascular mortality in hypertensive patients: insights from NHANES data with machine learning analysis","volume":"24","author":"Li","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B244","doi-asserted-by":"publisher","first-page":"108801","DOI":"10.1016\/j.pharmthera.2025.108801","article-title":"From physiology to pathology: Emerging roles of GPER in cardiovascular disease","volume":"267","author":"Wang","year":"2025","journal-title":"Pharmacol Ther"},{"key":"B245","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.scib.2025.01.016","article-title":"Enhancing panvascular medicine: unveiling the nexus of pan-cardio-oncology and expanding therapeutic frontiers","volume":"70","author":"Hu","year":"2025","journal-title":"Sci Bull"},{"key":"B246","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038659","article-title":"Autonomic dysfunction as manifestation of ICANS: A case report","volume":"103","author":"Rochate","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.3390\/biology13020105","article-title":"The intrinsic cardiac nervous system: from pathophysiology to therapeutic implications","volume":"13","author":"Giannino","year":"2024","journal-title":"Biol (Basel)"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1166022","article-title":"Effects of Litsea cubeba essential oil on growth performance, blood antioxidation, immune function, apparent digestibility of nutrients, and fecal microflora of pigs","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01070-0","article-title":"Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy","volume":"120","author":"Buehning","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors","volume":"74","author":"Ball","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27987","article-title":"Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome","volume":"3","author":"Kounis","year":"2014","journal-title":"Oncoimmunology"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1340373","article-title":"Immune checkpoint inhibitors associated cardiovascular immune-related adverse events","volume":"15","author":"Jo","year":"2024","journal-title":"Front Immunol"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1349081","article-title":"Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy","volume":"14","author":"Su","year":"2023","journal-title":"Front Pharmacol"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat Med"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01182-3","article-title":"Immune checkpoint-targeted antibodies: a room for dose and schedule optimization","volume":"15","author":"Maritaz","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B257","doi-asserted-by":"publisher","first-page":"104587","DOI":"10.1016\/j.critrevonc.2024.104587","article-title":"Cardiotoxicity associated with immune checkpoint inhibitors: Systematic review and meta-analysis","volume":"206","author":"Piazza","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ Res"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1130438","article-title":"Advances in immune checkpoint inhibitors induced-cardiotoxicity","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1161243","article-title":"Drug therapy for myocarditis induced by immune checkpoint inhibitors","volume":"14","author":"Wu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B261","doi-asserted-by":"publisher","first-page":"101527","DOI":"10.1016\/j.cpcardiol.2022.101527","article-title":"PD-1\/PD-L1 blockade accelerates the progression of atherosclerosis in cancer patients","volume":"48","author":"Dong","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040625","article-title":"Extensive CArdioVAscular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study","volume":"16","author":"Delombaerde","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1255825","article-title":"Immune-related cardiovascular toxicities of PD-1\/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1042\/CS20200331","article-title":"Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"135","author":"Baik","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e25747","article-title":"Immune checkpoint inhibitor-associated cardiovascular toxicities: A review","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: A guide for clinicians","volume":"46","author":"Raschi","year":"2023","journal-title":"Drug Saf"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B269","article-title":"2023 Chinese expert consensus on the impact of COVID-19 on the management of cardiovascular diseases","volume":"8","year":"2023","journal-title":"Cardiol Plus"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2022.6166","article-title":"Myocarditis or pericarditis events after BNT162b2 vaccination in individuals aged 12 to 17 years in ontario, Canada","volume":"177","author":"Buchan","year":"2023","journal-title":"JAMA Pediatr"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e317","article-title":"Epidemiological characteristics and outcome of myocarditis and pericarditis temporally associated with BNT162b2 COVID-19 vaccine in adolescents: korean national surveillance","volume":"39","author":"Ahn","year":"2024","journal-title":"J Kor Med Sci"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.16380","article-title":"Long-term prognosis of patients with myocarditis attributed to COVID-19 mRNA vaccination, SARS-coV-2 infection, or conventional etiologies","volume":"332","author":"Semenzato","year":"2024","journal-title":"JAMA"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5143","article-title":"Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: A phase 1 nonrandomized clinical trial","volume":"9","author":"Disis","year":"2023","journal-title":"JAMA Oncol"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16574","article-title":"Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors","volume":"8","author":"Ponomarenko","year":"2017","journal-title":"Oncotarget"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-110-3_27","article-title":"Safety assessment of biolistic DNA vaccination","volume":"940","author":"Langer","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B276","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"key":"B277","article-title":"Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients1","volume":"8","author":"Conry","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B278","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17040450","article-title":"Expanded spectrum and increased incidence of adverse events linked to COVID-19 genetic vaccines: new concepts on prophylactic immuno-gene therapy, iatrogenic orphan disease, and platform-inherent challenges","volume":"17","author":"Szebeni","year":"2025","journal-title":"Pharmaceutics"},{"key":"B279","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8010053","article-title":"Safety profile of a multi-antigenic DNA vaccine against hepatitis C virus","volume":"8","author":"Gummow","year":"2020","journal-title":"Vaccines"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122389","article-title":"Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result","volume":"14","author":"Jonny","year":"2023","journal-title":"Front Immunol"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1246682","article-title":"Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.980686","article-title":"DNA vaccine for cancer immunotherapy","volume":"10","author":"Yang","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness-A literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"B284","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological Malignancies: pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B285","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196124","article-title":"Exploring CAR-T cell therapy side effects: mechanisms and management strategies","volume":"12","author":"Zhang","year":"2023","journal-title":"J Clin Med"},{"key":"B286","article-title":"From the mechanism of action to clinical management: A review of cardiovascular toxicity in adult treated with CAR-T therapy","volume":"2025","author":"Nunes","year":"","journal-title":"Hematol Transfus Cell Ther"},{"key":"B287","doi-asserted-by":"crossref","DOI":"10.21037\/jtd.2018.12.78","article-title":"Cardio-toxicity of checkpoint inhibitors","volume":"10","author":"M\u00fcller","year":"2018","journal-title":"J Thorac Dis"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.962596","article-title":"Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges","volume":"13","author":"Gan","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1601808\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:15:09Z","timestamp":1750205709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1601808\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":288,"alternative-id":["10.3389\/fonc.2025.1601808"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1601808","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1601808"}}